Cell and Gene Therapy

Arovella Therapeutics and Cell Therapies collaborate to develop ALA101’s manufacturing process for use in clinical trials for cancer

Published November. 29. 2023

In order to develop the manufacturing process for Arovella’s ALA-101 product candidate—which is intended to treat cancer patients in upcoming clinical trials—Cell Therapies Pty Ltd has partnered with Arovella Therapeutics . 

The ALA-101 product combines a Chimeric Antigen Receptor (CAR) that targets CD19 with Arovella’s invariant natural killer T (iNKT) cell treatment platform from Imperial College London. The allogeneic cell treatment ALA-101 is being developed to offer a “off-the-shelf” remedy for malignancies that express CD19.

Cell Therapies will further develop Arovella’s  CAR-iNKT manufacturing process and advance it further in order to satisfy phase 1 clinical trial standards.

Source: Arovella Therapeutics

Get the free newsletter

Subscribe to IMAPAC for top news, trends & analysis